Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
29/08/2025
Galaxy Securities International: The target price of Meituan has been reduced from HK$161 to HK$123.
Latest
2 m ago
The trading volume of ETFs in the two cities exceeded 350 billion yuan.
2 m ago
UBS: China Taiping's first-half net profit exceeds expectations, target price raised to 41 Hong Kong dollars.
2 m ago
UBS research report pointed out that China Taiping's net profit for the first half of the year increased by 11% year on year, exceeding market expectations of 2% to 9% growth; operating surplus increased by 7.1%, slightly higher than UBS's forecast of 6% growth. The growth in new business value in the first half of the year increased by 32% year on year, in line with expectations. In terms of comparable basis, the growth of Taiping's new business value slowed down in the second quarter, UBS attributed this to the slowdown in first-year premium growth on a quarterly basis, but performance remains strong. In response to the recent rise in China Taiping's stock price, UBS raised its intrinsic value forecast for 2025 by 5% and raised its target price from HK$37 to HK$41, with a "Buy" rating.
3 m ago
In the afternoon, the biological products sector of A-shares rose sharply, with Rongchang Biological up more than 12%, Maiwei Biological up 9% in a straight line, Kangchen Pharmaceutical previously hit the limit up, Sanheliu Health, Wanze Shares, Sanyuan Gene and others all rose more than 6%.
3 m ago
ST Zhongji: The company's production and operations have been normal recently, and there have been no significant changes in the internal and external business environment.
See all latest
